-transparent.png){kind=logo}
In naive mice, ibogaine at a tremorigenic dose (30 mg/kg, ip), did not produce antinociception but did potentiate the antinociceptive potency of morphine in the tail-flick test. In morphine-dependent mice, ibogaine did not eliminate withdrawal symptoms but significantly increased the number of repetitive vertical jumps induced by naloxone, whatever the duration of the chronic morphine treatment. By comparison, repetitive jumping induced by alpha-napthoxyacetic acid (alpha-NOAA), a non-convulsant drug which induced jumping without affecting other morphine-withdrawal signs, was not significantly modified by ibogaine. These results indicate that while acute antinociceptive effects of morphine are modulated by ibogaine, this drug, shown to alleviate opiate dependence in man, does not attenuate in mice opioid withdrawal manifestations.
B Francés, and
R Gout, and
J Cros, and
J M Zajac
January 1988,
Archives internationales de pharmacodynamie et de therapie,
B Francés, and
R Gout, and
J Cros, and
J M Zajac
January 1990,
NIDA research monograph,
B Francés, and
R Gout, and
J Cros, and
J M Zajac
September 1990,
Neuroreport,
B Francés, and
R Gout, and
J Cros, and
J M Zajac
January 2011,
Neuroscience letters,
B Francés, and
R Gout, and
J Cros, and
J M Zajac
May 1996,
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
B Francés, and
R Gout, and
J Cros, and
J M Zajac
June 2010,
Neuropeptides,
B Francés, and
R Gout, and
J Cros, and
J M Zajac
February 2002,
Progress in neuro-psychopharmacology & biological psychiatry,
B Francés, and
R Gout, and
J Cros, and
J M Zajac
November 1995,
General pharmacology,
B Francés, and
R Gout, and
J Cros, and
J M Zajac
December 2014,
Psychopharmacology,
B Francés, and
R Gout, and
J Cros, and
J M Zajac
January 2022,
Journal of neuroscience research,
